查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566976

尿激酶市场：按类型、最终用户划分：2024-2033 年全球机会分析与产业预测

Urokinase Market By Type (Urokinase Powder, Urokinase Solution) , By End User (Hospital, Clinics) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

尿激酶市场

2023年尿激酶市值为18亿美元，预计2024年至2033年复合年增长率为5.7%，到2033年达到31亿美元。

尿激酶是一种溶栓药物，可以帮助身体产生溶解血栓所需的物质。从化学上讲，尿激酶是丝胺酸蛋白酶，也称为尿激酶型胞浆素原原激活剂（uPA）。这种化合物最初是从人类尿液中分离出来的，存在于血液和多种组织的细胞外基质中。该药物透过静脉注射，并在密切的医疗监督下给药。用于治疗肺动脉栓塞、急性心肌梗塞、深层静脉栓塞症等。

由于老年人口的迅速增加和生活方式的显着变化，心血管疾病的盛行率不断增加，这是尿激酶市场的主要驱动因素。此外，配方的改进和药物传输系统的进步正在推动对尿激酶作为有效治疗解决方案的需求。目前，市场趋势是扩大尿激酶的治疗范围，尿激酶已被证明对原发性肾病症候群和结核性胸膜炎的治疗有效。在结核性胸膜炎的治疗中，抗结核治疗与尿激酶合併治疗的效果相对优于单一治疗。合併使用尿激酶可减少残留胸膜厚度，增加胸水总量，改善肺功能，缩短胸水吸收时间。在原发性肾病症候群中，尿激酶可预防静脉血栓栓塞症，这也与轻微出血事件有关。

然而，出血併发症的风险仍然很大，限制了尿激酶市场的成长。此外，现代抗凝血疗法和组织胞浆素原原激活剂（tPA）等替代疗法的盛行对市场开拓提出了重大挑战。另一方面，改进配方的持续研发努力正在透过改进配方、减少副作用并提高患者依从性，为市场扩张创造新的机会。例如，一种新的尿激酶前体，称为尿激酶原，目前正在进行临床试验。已知这种惰性的前驱物在其转化为活性尿激酶的过程中确保纤维蛋白特异性生理特性的参与，从而提高药物的功效。

按部门审查

尿激酶市场按类型、最终用户和地区细分。按类型划分，市场分为尿激酶粉和尿激酶溶液。依最终使用者分为医院和诊所。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按类型划分，尿激酶溶液细分市场在 2023 年占据主导地位。

以最终用户计算，到 2023 年，医院部门将成为最大股东。

按地区划分，亚太地区市场正在迅速扩张。

可以自订此报告（需要额外的费用和时间表）

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章尿激酶市场：依类型

  • 市场概况
  • 尿激酶粉
  • 尿激酶溶液

第五章 尿激酶市场：依最终使用者分类

  • 市场概况
  • 医院
  • 诊所

第六章 尿激酶市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国尿激酶市场
    • 加拿大尿激酶市场
    • 墨西哥尿激酶市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国尿激酶市场
    • 法国尿激酶市场
    • 英国尿激酶市场
    • 义大利尿激酶市场
    • 西班牙尿激酶市场
    • 其他欧洲尿激酶市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本尿激酶市场
    • 中国尿激酶市场
    • 澳洲尿激酶市场
    • 印度尿激酶市场
    • 韩国尿激酶市场
    • 其他亚太尿激酶市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西尿激酶市场
    • 沙乌地尿激酶市场
    • 南非尿激酶市场
    • 其他拉丁美洲/中东/非洲尿激酶市场

第七章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第八章 公司简介

  • NDpharm
  • Wanhua Biochem
  • Jiangxi Haoran Bio-Pharma
  • Jiangsu Aidea Pharmaceutical
  • Techpool
  • Microbic Biosystems Inc
  • Livzon Pharmaceutical Group Inc.
  • Cadila Healthcare Limited
  • TAJ Pharmaceuticals Limited
  • Microbix Biosystems Inc
简介目录
Product Code: A324534

Urokinase Market

The urokinase market was valued at $1.8 billion in 2023 and is projected to reach $3.1 billion by 2033, growing at a CAGR of 5.7% from 2024 to 2033.

Urokinase is a clot-busting drug which helps the body produce substances necessary to dissolve blood clots. Chemically, urokinase is a serine protease and is also known as urokinase-type plasminogen activator (uPA). The compound was initially isolated from human urine and is present in blood & extracellular matrix of several tissues. The drug is injected intravenously and is strictly administered under medical supervision. The drug is used to treat several conditions such as pulmonary embolism, acute myocardial infarction, and deep vein thrombosis.

Increase in the prevalence of cardiovascular disorders owing to exponentially growing elderly population and significantly changing lifestyle is a major driver of the urokinase market. In addition, improvements in formulation and advancements in drug delivery systems are boosting the demand for urokinase as an efficient treatment solution. Expansion of the treatment horizon of urokinase is currently trending in the market, with the drug proving to be beneficial for the treatment of primary nephrotic syndrome and tuberculous pleurisy. The combined effect of the drug and antituberculous therapy is comparatively better for the treatment of tuberculous pleurisy, than the therapy alone. The integration of urokinase decreases residual pleural thickness, increases total pleural effusion, improves pulmonary function, and reduces pleural effusion absorption time. In primary nephrotic syndrome, urokinase prevents venous thromboembolism, coupled with minor bleeding events.

However, the risk of bleeding complications remains significant in various individuals, thereby restraining the growth of the urokinase market. Moreover, the predominant usage of alternatives, including latest anticoagulant therapies and tissue plasminogen activator (tPA), is presenting significant challenges for the market development. On the contrary, constant R&D efforts toward the refinement of formulations are presenting novel opportunities for market expansion as these improved formulations exhibit less side effects and enhance the patient compliance. For instance, a fresh precursor of urokinase, known as pro-urokinase, is under clinical trials currently. This inactive precursor ensures the involvement of its fibrin-specific physiologic properties during conversion into active urokinase that are known to enhance the efficacy of the drug.

Segment Review

The urokinase market is segmented into type, end user, and region. On the basis of type, the market is bifurcated into urokinase powder and urokinase solution. As per end user, it is divided into hospital and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the urokinase solution segment dominated the market in 2023.

As per end user, the hospital segment was the highest shareholder in 2023.

Region wise, the market is witnessing rapid expansion in Asia-Pacific.

Competition Analysis

The leading players operating in the global urokinase market include NDpharm, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems Inc, Livzon Pharmaceutical Group Inc., Cadila Healthcare Limited, TAJ Pharmaceuticals Limited, and Microbix Biosystems Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Urokinase Powder
  • Urokinase Solution

By End User

  • Hospital
  • Clinics

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • NDpharm
    • Wanhua Biochem
    • Jiangxi Haoran Bio-Pharma
    • Jiangsu Aidea Pharmaceutical
    • Techpool
    • Microbic Biosystems Inc
    • Livzon Pharmaceutical Group Inc.
    • Cadila Healthcare Limited
    • TAJ Pharmaceuticals Limited
    • Microbix Biosystems Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: UROKINASE MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Urokinase Powder
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Urokinase Solution
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: UROKINASE MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospital
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Clinics
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: UROKINASE MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Urokinase Market
      • 6.2.5.1. Market Size and Forecast, By Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Urokinase Market
      • 6.2.6.1. Market Size and Forecast, By Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Urokinase Market
      • 6.2.7.1. Market Size and Forecast, By Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Urokinase Market
      • 6.3.5.1. Market Size and Forecast, By Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Urokinase Market
      • 6.3.6.1. Market Size and Forecast, By Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Urokinase Market
      • 6.3.7.1. Market Size and Forecast, By Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Urokinase Market
      • 6.3.8.1. Market Size and Forecast, By Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Urokinase Market
      • 6.3.9.1. Market Size and Forecast, By Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Urokinase Market
      • 6.3.10.1. Market Size and Forecast, By Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Urokinase Market
      • 6.4.5.1. Market Size and Forecast, By Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Urokinase Market
      • 6.4.6.1. Market Size and Forecast, By Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Urokinase Market
      • 6.4.7.1. Market Size and Forecast, By Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Urokinase Market
      • 6.4.8.1. Market Size and Forecast, By Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Urokinase Market
      • 6.4.9.1. Market Size and Forecast, By Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Urokinase Market
      • 6.4.10.1. Market Size and Forecast, By Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Urokinase Market
      • 6.5.5.1. Market Size and Forecast, By Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Urokinase Market
      • 6.5.6.1. Market Size and Forecast, By Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Urokinase Market
      • 6.5.7.1. Market Size and Forecast, By Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Urokinase Market
      • 6.5.8.1. Market Size and Forecast, By Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. NDpharm
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Wanhua Biochem
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Jiangxi Haoran Bio-Pharma
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Jiangsu Aidea Pharmaceutical
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Techpool
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Microbic Biosystems Inc
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Livzon Pharmaceutical Group Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Cadila Healthcare Limited
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. TAJ Pharmaceuticals Limited
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Microbix Biosystems Inc
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments